Lancet Neurology publishes results of AFFiRiS' Phase 1 trial with PD01A in Parkinson's

(MC Services AG) AFFiRiS AG, a clinical-stage biotechnology company developing novel disease-modifying specific active immunotherapies (SAITs), today announced that detailed results of the phase 1 clinical program with its lead candidate PD01 in early Parkinson's disease (PD) patients were published in the peer-reviewed journal The Lancet Neurology